Vycor Medical, Inc. provides surgical and therapeutic solutions. The Company operates through two segments: Vycor Medical, which focuses on brain and cervical surgical access systems for sale to hospitals and medical professionals, and NovaVision, which focuses on neuro-stimulation therapies and diagnostic devices for the treatment and screening of vision field loss resulting from neurological damage. The Company designs, develops and markets neurological medical devices and therapies. The Company operates in the United States and Europe. Vycor Medical's product Vycor Medical's ViewSite Brain Access System (VBAS) is a next generation retraction and access system. VBAS is a disposable product that can be used with microscopic, endoscopic and neuro-navigation systems. NovaVision has a family of therapies that both restore and compensate for lost vision. NovaVision's products include VRT and Neuro-Eye Therapy (NeET), NeuroEyeCoach and Vision Diagnostic (VIDIT).
Industry, Sector and Symbol:
- Market Cap: $5.75 million
- Outstanding Shares: 19,170,000
- 50 Day Moving Avg: $0.26
- 200 Day Moving Avg: $0.23
- 52 Week Range: $0.12 - $0.45
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: $1.48 million
- Price / Sales: 3.89
- Book Value: $0.04 per share
- Price / Book: 7.50
- EBIDTA: ($1,100,000.00)
- Net Margins: -73.01%
- Return on Equity: -526.03%
- Return on Assets: -70.37%
- Average Volume: 2,452 shs.
Frequently Asked Questions for Vycor Medical (OTCMKTS:VYCO)
What is Vycor Medical's stock symbol?
Vycor Medical trades on the OTCMKTS under the ticker symbol "VYCO."
When will Vycor Medical make its next earnings announcement?
Who are some of Vycor Medical's key competitors?
Some companies that are related to Vycor Medical include usell.com (USEL), Abengoa Sa (ABGOY), Gleacher & Co. (GLCH), Abtech Holdings (ABHD), Talon International (TALN), Noble Roman's (NROM), Cool Technologies (WARM), Acorn Energy (ACFN), Vantage Drilling (VTGDF), Omnitek Engineering Corp. (OMTK), Affymax (AFFY), Black Ridge Oil & Gas (ANFC), Prospect Global Resources (PGRX), Air Canada Var Vtg (AIDIF), American Airlines Group (AAMRQ), Anglo American Platinum Ltd (AGPPY), Antofagasta plc (ANFGY) and Atna Resources Ltd (ATNAF).
Who are Vycor Medical's key executives?
Vycor Medical's management team includes the folowing people:
- Adrian Christopher Liddell, Chairman of the Board, Chief Financial Officer
- David Marc Cantor, President, Director
- Peter C. Zachariou, Chief Executive Officer, Executive Vice President, Director
- Oscar L. Bronsther M.D., Independent Director
- Steven Girgenti, Independent Director
- Lowell Rush, Independent Director
How do I buy Vycor Medical stock?
Shares of Vycor Medical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vycor Medical's stock price today?
MarketBeat Community Rating for Vycor Medical (OTCMKTS VYCO)MarketBeat's community ratings are surveys of what our community members think about Vycor Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Vycor Medical stock can currently be purchased for approximately $0.30.
Consensus Ratings for Vycor Medical (OTCMKTS:VYCO) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Vycor Medical (OTCMKTS:VYCO)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Vycor Medical (OTCMKTS:VYCO)Earnings History by Quarter for Vycor Medical (OTCMKTS VYCO)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Vycor Medical (OTCMKTS:VYCO)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Vycor Medical (OTCMKTS:VYCO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Vycor Medical (OTCMKTS:VYCO)Insider Trades by Quarter for Vycor Medical (OTCMKTS:VYCO)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/31/2014||Fountainhead Capital Managemen||Major Shareholder||Buy||8,380||$1.79||$15,000.20|| |
|10/6/2014||Fountainhead Capital Managemen||Major Shareholder||Buy||6,383||$2.35||$15,000.05|| |
|6/30/2014||Fountainhead Capital Managemen||Major Shareholder||Buy||6,329||$1.80||$11,392.20|| |
|3/31/2014||Fountainhead Capital Managemen||Major Shareholder||Buy||6,276||$1.80||$11,296.80|| |
|1/2/2014||Fountainhead Capital Managemen||Major Shareholder||Buy||792,523||$1.80||$1,426,541.40|| |
Headline Trends for Vycor Medical (OTCMKTS:VYCO)
Latest Headlines for Vycor Medical (OTCMKTS:VYCO)
|Vycor Medical, Inc. :VYCO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017|
finance.yahoo.com - May 27 at 6:43 AM
|Vycor Medical Reports Financial Results for the Period Ended March 31st, 2017|
finance.yahoo.com - May 12 at 4:22 AM
|Vycor Medical, Inc. :VYCO-US: Earnings Analysis: Q4, 2016 By the Numbers : April 11, 2017|
finance.yahoo.com - April 11 at 9:35 PM
|VYCOR MEDICAL INC Files SEC form 10-K, Annual Report|
biz.yahoo.com - April 1 at 9:58 AM
|Vycor Medical Reports Financial Results for the Year Ended December 31st, 2016|
finance.yahoo.com - April 1 at 9:58 AM
|VYCOR MEDICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securit|
biz.yahoo.com - January 13 at 5:55 AM
|VYCOR MEDICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Principal|
biz.yahoo.com - November 14 at 8:33 PM
|Vycor Medical Reports Financial Results for the Three and Nine Months Ended September 30th, 2016|
finance.yahoo.com - November 14 at 12:35 PM
|VYCOR MEDICAL INC Files SEC form 10-K/A, Annual Report|
biz.yahoo.com - November 8 at 8:18 PM
|New Clinical Study on NeuroEyeCoach Conclusively Supports Meaningful Improvement in Eye Movement Efficiency|
finance.yahoo.com - September 28 at 7:49 PM
|Vycor Medical Reports Financial Results for the Three Months Ended March 31st, 2016|
finance.yahoo.com - April 28 at 9:00 AM
|Vycor Medical Reports Financial Results for the Year Ended December 31st, 2015|
finance.yahoo.com - March 30 at 9:56 AM
|VYCOR MEDICAL INC Files SEC form 8-K, Results of Operations and Financial Condition|
biz.yahoo.com - March 30 at 8:31 AM
|Vycor Medical Launches VBASMini|
finance.yahoo.com - March 16 at 9:43 AM
|VYCOR MEDICAL INC Financials|
finance.yahoo.com - December 8 at 1:18 PM
|Vycor Medical's NovaVision Launches its European Internet-Delivered Therapy Suite at the 3rd European Conference of NeuroRehabilitation|
finance.yahoo.com - November 30 at 8:00 AM
|New Clinical Data Released at the World Congress of Neuroendoscopy Conclusively Points to Vycor's VBAS Reducing Post Operative Patient Length of Stay in Hospital|
finance.yahoo.com - November 18 at 8:02 AM
|VYCOR MEDICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit|
biz.yahoo.com - November 13 at 2:23 PM
|Vycor Medical Reports Third Quarter 2015 Results|
finance.yahoo.com - November 13 at 8:30 AM
|VYCOR MEDICAL INC Files SEC form 10-Q, Quarterly Report|
biz.yahoo.com - November 13 at 7:33 AM
|New Clinical Data in Japan Demonstrates Benefits of Using Vycor Medical's VBAS with Karl Storz's VITOM Exoscope for Surgery of Deep-Seated Tumors|
finance.yahoo.com - October 28 at 8:00 AM
|Vycor Medical's NovaVision Unveils Its European Internet-Delivered Therapy Suite at the 30th Annual GNP Conference|
finance.yahoo.com - September 30 at 8:30 AM
|Vycor Medical to Unveil VBAS Product Line Extension and Prototypes at CNS 65th Annual Meeting in New Orleans, September 26-30, 2015|
finance.yahoo.com - September 25 at 8:30 AM
|Vycor Medical to Present at the 4th Annual Liolios Gateway Conference on September 10, 2015|
finance.yahoo.com - August 31 at 8:31 AM
|Vycor Medical Reports Second Quarter 2015 Results|
finance.yahoo.com - August 14 at 5:00 PM
|World Neurosurgery Publishes New Clinical Study Performed at the Walter Reed National Military Medical Center Showing Positive Performance of Vycor's VBAS in the Treatment of Wartime Brain Injuries|
finance.yahoo.com - August 12 at 10:10 AM
|VYCOR MEDICAL INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits|
biz.yahoo.com - July 24 at 4:37 PM
Vycor Medical (VYCO) Chart for Wednesday, July, 26, 2017